Intraperitoneal paclitaxel in the management of ovarian cancer.

@article{Markman1995IntraperitonealPI,
  title={Intraperitoneal paclitaxel in the management of ovarian cancer.},
  author={Maurie Markman},
  journal={Seminars in oncology},
  year={1995},
  volume={22 5 Suppl 12},
  pages={86-7}
}
For several reasons, including its demonstrated activity in ovarian cancer, large size, hepatic metabolism, and lack of vesicant properties, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is an interesting agent to consider for intraperitoneal administration in the management of ovarian cancer. Two phase I trials have confirmed a major pharmacokinetic advantage (> or = 1,000-fold) for peritoneal cavity exposure compared with the systemic compartment following intraperitoneal… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…